MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment

NCT02333578 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2015-01-07

No results posted yet for this study

Summary

A Phase I/II Pilot Clinical Trial to Evaluate the Efficacy and Safety of Ebola Virus Disease (EVD) Convalescent Plasma (ECP) for treatment of EVD.

Conditions

  • Ebola Virus Disease

Interventions

PROCEDURE

Convalescent Plasma Treatment

This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).

Sponsors & Collaborators

  • Clinical Research Management, Inc.

    lead INDUSTRY

Principal Investigators

  • Jerry Brown, MD · ELWA Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-04-30
Completion
2015-06-30

Countries

  • Liberia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02333578 on ClinicalTrials.gov